Investors advised to buy 200-day dip in ARM, MSTR, VKTX for potential bounce back

From Nasdaq

September 9, 2024 6:14:00 PM:

Investors can benefit from simplifying their approach by focusing on the 200-day moving average indicator. This tool, praised by billionaire investor Paul Tudor Jones, helps identify trends, manage risk, and improve timing. Three key reasons to use this indicator include trend identification, risk management, and timing capabilities.

MicroStrategy, a popular Bitcoin proxy, is testing the 200-day moving average after a significant rally. The stock has shown impressive relative strength compared to other crypto proxies like Coinbase and Bitfarms. Bullish options flow suggests that the pullback could be temporary, making it an attractive buy opportunity.

Despite inflated valuations in today’s market, Arm Holdings stands out as a rare gem. The AI company has doubled since its IPO and is approaching the 200-day moving average. Bullish options activity in ARM indicates a potential bounce back from the recent pullback, supported by a history of positive EPS surprises.

Viking Therapeutics surprised the market with positive Phase 2 trial results for its weight loss drug, leading to a significant stock price increase. As the stock consolidates, nearing its 200-day moving average, upcoming data releases during “Obesity Week” could serve as a catalyst for further gains. Viking could challenge giants like Novo Nordisk and Eli Lilly in the obesity drug market.

Read more at Nasdaq: Why you Should Buy the 200-day Dip in ARM, MSTR, VKTX